N-(4-((1S)-1-((R)-(4-Chlorophenyl)(7-fluoro-5-methyl-1H-indol-3-yl)methyl)butyl)benzoyl)-beta-alanine | 1019112-29-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: N-(4-((1S)-1-((R)-(4-Chlorophenyl)(7-fluoro-5-methyl-1H-indol-3-yl)methyl)butyl)benzoyl)-beta-alanine
• 英文别名: 3-[[4-[(1R,2S)-1-(4-chlorophenyl)-1-(7-fluoro-5-methyl-1H-indol-3-yl)pentan-2-yl]benzoyl]amino]propanoic acid
• CAS: 1019112-29-8
• 化学式: C₃₀H₃₀ClFN₂O₃
• 分子量: 521.0
• InChiKey: FYRJJCYFYLLOSC-LXFBAYGMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  37
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  82.2
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  methyl N-(4-(2-(4-chlorophenyl)-4-oxo-1-propylbutyl)benzoyl)-β-alaninate 、 salmon MCH 、 (2-氟-4-甲基苯基)肼盐酸盐 在 氯化锌 乙酸乙酯 、 水 、 Brine 、 Sodium sulfate-III 、 silica gel 作用下， 以 溶剂黄146 为溶剂， 反应 0.75h， 生成 N-(4-((1S)-1-((R)-(4-Chlorophenyl)(7-fluoro-5-methyl-1H-indol-3-yl)methyl)butyl)benzoyl)-beta-alanine
  参考文献：
  名称：

  GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

  摘要：

  本文披露了一种胰高血糖素受体拮抗剂化合物。该化合物可用于治疗2型糖尿病及相关疾病。本文还包括制药组合物和治疗方法。

  公开号：

  US20100004158A1

文献信息

• [EN] ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS D'HÉTÉROARYLE SUBSTITUÉ ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015095256A1

  公开（公告）日：2015-06-25

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  本发明涉及一种由公式（I）表示的化合物：以及药学上可接受的盐。公式I的化合物是G蛋白偶联受体40（GPR40）的激动剂，并且可能对由G蛋白偶联受体40介导的疾病的治疗、预防和抑制有用。本发明的化合物可能在治疗2型糖尿病，以及通常与该疾病相关的状况，包括肥胖和脂质紊乱，如混合型或糖尿病性血脂异常、高脂血症、高胆固醇血症和高甘油三酯血症中有用。
• HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Isabel Elise

  公开号：US20110301143A1

  公开（公告）日：2011-12-08

  Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R 1 — substituted heteroaryl, R 1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR 5 R 6 , C═CR 5 or CR 13 —CR 5 R 6 , Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

  结构式（I）的杂环化合物，或其药学上可接受的盐，其中W是R1-取代的杂芳基，R1是取代有酯基或羧基的杂芳基环，X-T是N—CR5R6，C═CR5或CR13—CR5R6，Y是键或—C(O)—，a和b代表选自1到4的整数，Ar是可选择取代的苯基或萘基，是硬脂酰辅酶A 9-脱饱和酶（SCD）的抑制剂。这些杂环化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病、动脉粥样硬化、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗、癌症、肝脂肪变性和非酒精性脂肪肝。
• AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
  申请人：Biftu Tesfaye

  公开号：US20100120863A1

  公开（公告）日：2010-05-13

  The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基四氢吡喃衍生物，它们是二肽基肽酶-IV酶的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。
• [EN] ANTIDIABETIC TRICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS TRICYCLIQUES ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2015176267A1

  公开（公告）日：2015-11-26

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR 40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds may be useful in the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR 40）的激动剂，可能在治疗、预防和抑制由G蛋白偶联受体40介导的疾病方面有用。这些化合物可能在治疗2型糖尿病以及通常与该疾病相关的疾病，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症方面有用。
• [EN] GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF USE<br/>[FR] COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DU GLUCAGON, COMPOSITIONS CORRESPODANTES ET MÉTHODES D'UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2015066252A1

  公开（公告）日：2015-05-07

  Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  抗胰高血糖素受体化合物具有长效作用。这些化合物可用于治疗2型糖尿病及相关疾病。药物组合和治疗方法也包括在内。